Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Total Non-Current Liabilities (2016 - 2026)

Oramed Pharmaceuticals filings provide 15 years of Total Non-Current Liabilities readings, the most recent being $12.0 million for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 183.42% to $12.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.0 million through Dec 2025, up 183.42% year-over-year, with the annual reading at $12.0 million for FY2025, 183.42% up from the prior year.
  • Total Non-Current Liabilities hit $12.0 million in Q4 2025 for Oramed Pharmaceuticals, roughly flat from $12.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $12.0 million in Q3 2025 and bottomed at $2.2 million in Q1 2025.
  • Average Total Non-Current Liabilities over 5 years is $5.1 million, with a median of $4.5 million recorded in 2023.
  • Peak annual rise in Total Non-Current Liabilities hit 183.42% in 2025, while the deepest fall reached 50.79% in 2025.
  • Oramed Pharmaceuticals' Total Non-Current Liabilities stood at $4.1 million in 2021, then rose by 15.64% to $4.7 million in 2022, then fell by 6.24% to $4.4 million in 2023, then fell by 4.46% to $4.2 million in 2024, then skyrocketed by 183.42% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Total Non-Current Liabilities are $12.0 million (Q4 2025), $12.0 million (Q3 2025), and $4.4 million (Q2 2025).